BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 18, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2019

View Archived Issues

CD16-IL-15-CLEC12A TriKE demonstrates preclinical activity in models of AML

Read More

PTMs affect, as well as are affected by, protein folding

Read More

Gut-derived plasma cells suppress MS

Read More

Discontinuing tumor treatment can push cells into temporary retirement

Read More

BlackThorn Therapeutics offers pipeline update

Read More

BCAR3 as novel biomarker of prognosis in patients with multiple myeloma

Read More

Final safety results presented from phase I study of BT-11 in healthy volunteers

Read More

SH-498 presented as a promising anti-BMI-1 compound for colorectal cancer

Read More

Incyte begins phase I study of INCB-086550 in advanced solid tumors

Read More

Homology Medicines nominates in vivo gene editing development candidate for PKU

Read More

Epclusa approved in Japan for HCV

Read More

Forbius initiates phase I trial of AVID-200 in solid tumors

Read More

Etrasimod demonstrates long-term clinical remission in phase II OLE study for ulcerative colitis

Read More

Phase III study of SAGE-217 in postpartum depression meets primary and secondary endpoints

Read More

ProQR agrees with FDA on phase II/III trial design for QR-110 in Leber's congenital amaurosis 10

Read More

LINC00165 shown to promote progression of gastric cancer

Read More

FDA clears PrimeVax's IND for first-in-human trial in melanoma

Read More

FDA accepts IND for bispecific antibody MCLA-145

Read More

ContraFect reports topline phase II results for exebacase in S. aureus bacteremia

Read More

Promising phase II data presented for AK-002 in Xolair-naive chronic spontaneous urticaria patients

Read More

Minnebro approved in Japan for hypertension

Read More

Universite Laval patents IL-6 expression inhibitors

Read More

Quretech Bio AB and Washington University present new antibacterials

Read More

Novartis AG discloses new compounds for protozoal infections

Read More

Phase II ASCEND study of AXS-05 in major depressive disorder meets primary endpoint

Read More

Zhejiang Hisun Pharmaceutical describes ACC inhibitors

Read More

CIMA presents new compounds for cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing